Tezacaftor and ivacaftor for the treatment of cystic fibrosis.

Abstract:

:Introduction: Cystic fibrosis (CF) is a complex, multi-system, genetic disease affecting over 70,000 people worldwide. The underlying defect is a mutation in the CFTR gene. Dysfunctional CFTR protein results in abnormal anion movement across epithelial membranes in affected organs. There has been a paradigm shift in CF treatment over the last decade with the advent of CFTR modulation, treatments which target this underlying genetic defect and have the potential to change the course of CF clinical disease.Areas covered: Available CFTR modulators in current clinical practice are reviewed in this article, with a direct comparison and summary of relevant pivotal clinical trials. The approval of ivacaftor and subsequent development of lumacaftor and tezacaftor dual combinations represents an exciting development in CF management in recent years.Expert opinion: Tezacaftor/ivacaftor (tez/iva) appears to have a more favorable adverse event and drug-drug interaction profile than lumacaftor/ivacaftor. Tez/iva has been approved, alongside Phe508del, for a large number of 'residual function' CFTR mutations, with some based on response to in vitro culture. Dual therapy with tez/iva has paved the way for triple CFTR modulation currently in clinical trials with an ultimate view to provide modulation therapy to the majority of CF genotypes in the future.

journal_name

Expert Rev Respir Med

authors

Paterson SL,Barry PJ,Horsley AR

doi

10.1080/17476348.2020.1682998

subject

Has Abstract

pub_date

2020-01-01 00:00:00

pages

15-30

issue

1

eissn

1747-6348

issn

1747-6356

journal_volume

14

pub_type

杂志文章,评审
  • COPD updates: what's new in pathophysiology and management?

    abstract::The historic perspective that used to define chronic obstructive pulmonary disease has changed. As reviewed in this article, it is based on a better understanding of the underlying inflammatory airflow obstruction and a multidimensional classification, which mostly targets a subgroup called 'frequent exacerbators'. Cl...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/17476348.2013.814392

    authors: Noujeim C,Bou-Khalil P

    更新日期:2013-08-01 00:00:00

  • Combination therapy for the treatment of pulmonary mold infections.

    abstract:INTRODUCTION:Pulmonary mold infections are caused by ubiquitous organisms found in soil, water, and decaying vegetation, including Aspergillus spp., the Mucormycetes, hyaline molds, and dematiaceous (black) molds. Areas covered: These infections are often a challenge to diagnose and even more difficult to treat. Recent...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2017.1325322

    authors: McCarthy MW,Petraitis V,Walsh TJ

    更新日期:2017-06-01 00:00:00

  • Genetics and genomics in human lung transplantation.

    abstract::Lung transplantation is the only effective treatment for many advanced lung diseases. However, long-term survival after transplantation remains relatively poor, thus limiting the application of lung transplantation to patients with end-stage disease only. Acute and chronic rejection is the main reason for allograft fa...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.1.2.271

    authors: Garantziotis S,Palmer SM

    更新日期:2007-10-01 00:00:00

  • Smoking and nonsmoking asthma: differences in clinical outcome and pathogenesis.

    abstract::Cigarette smoking in asthma is frequently present and is associated with worsening of symptoms, accelerated lung-function decline, a higher frequency of hospital admissions, a higher degree of asthma severity, poorer asthma control and reduced responsiveness to corticosteroids. Furthermore, it is associated with reduc...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.10.85

    authors: Fattahi F,Hylkema MN,Melgert BN,Timens W,Postma DS,ten Hacken NH

    更新日期:2011-02-01 00:00:00

  • Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease.

    abstract::Erdosteine is a multimechanism, mucolytic agent that decreases the sputum viscoelastic properties and bacterial adhesion to the cell membrane, endowed with bronchial anti-inflammatory activity and a scavenging effect on free oxidant radicals. Erdosteine is a prodrug and metabolite I is the active metabolite of erdoste...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.1.3.307

    authors: Moretti M

    更新日期:2007-12-01 00:00:00

  • Pharmacological treatment of refractory breathlessness.

    abstract::Refractory breathlessness is one of the most common and devastating symptoms of advanced cardiorespiratory disease, both malignant and nonmalignant. In spite of increased interest in research in the last 20 years, there have been few significant advances in the palliation of this distressing condition. The most succes...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.3.1.21

    authors: Booth S,Bausewein C,Higginson I,Moosavi SH

    更新日期:2009-02-01 00:00:00

  • The role of beta-blockers in the management of chronic obstructive pulmonary disease.

    abstract:INTRODUCTION:The use of beta-blockers in chronic obstructive pulmonary disease (COPD) is controversial, primarily due to concerns that they may worsen lung function and attenuate bronchodilator response. Areas covered: This review summarizes the reasons for and against the use of beta-blockers in COPD by evaluating the...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1419869

    authors: Leitao Filho FS,Alotaibi NM,Yamasaki K,Ngan DA,Sin DD

    更新日期:2018-02-01 00:00:00

  • Combination therapy in pulmonary arterial hypertension: do we have the right strategy?

    abstract::The management of pulmonary hypertension has already incorporated the use of multiple therapies into routine practice. Available therapies act principally through vasodilatation of the pulmonary arterial circulation through well-delineated mechanisms, although right ventricular function determines function and prognos...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.11.13

    authors: Mukherjee B,Howard L

    更新日期:2011-04-01 00:00:00

  • Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.

    abstract::Premature infants are at substantial risk for a spectrum of morbidities that are gestational age dependent. Respiratory syncytial virus (RSV) infection is most common in the first two years of life with the highest burden in children aged <6 months. Preterm infants ≤35 weeks' gestation are handicapped by incomplete im...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/17476348.2015.1098536

    authors: Abraha HY,Lanctôt KL,Paes B

    更新日期:2015-01-01 00:00:00

  • Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.

    abstract::Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have significantly improved the survival of patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR activating mutations. However, nearly all EGFR-mutant NSCLC tumors eventually acquire resistance to the currently used EGFR-TKIs a...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/17476348.2016.1164603

    authors: Noda S,Kanda S

    更新日期:2016-01-01 00:00:00

  • Morning symptoms in COPD: a treatable yet often overlooked factor.

    abstract:INTRODUCTION:Chronic obstructive pulmonary disease (COPD) patients experience the morning as the worst period of the day. Nevertheless, morning symptoms are not mentioned in COPD guidelines. Areas covered: Different topics on morning symptoms are covered in this review to underline their importance: occurrence, tools f...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2017.1305894

    authors: van Buul AR,Kasteleyn MJ,Chavannes NH,Taube C

    更新日期:2017-04-01 00:00:00

  • Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

    abstract:INTRODUCTION:The treatment of lung cancer has radically changed over the last few years. The discovery of druggable oncogenic alterations and the introduction of immunotherapy have provided lung cancer patients with the possibility of more efficient and less toxic therapeutic alternatives than chemotherapy. In the case...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2017.1326822

    authors: Lazzari C,Karachaliou N,Gregorc V,Bulotta A,Gonzalez-Cao M,Verlicchi A,Altavilla G,Rosell R,Santarpia M

    更新日期:2017-06-01 00:00:00

  • Risks associated with lung transplantation in cystic fibrosis patients.

    abstract:INTRODUCTION:Survival after lung transplantation lags behind outcomes of other solid organ transplants, and complications from lung transplant are the second most common cause of death in cystic fibrosis. Evolving surgical techniques, therapeutics, and perioperative management have improved short-term survival after lu...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1522254

    authors: Li SS,Tumin D,Krone KA,Boyer D,Kirkby SE,Mansour HM,Hayes D Jr

    更新日期:2018-11-01 00:00:00

  • Emerging biomarkers of lymphangioleiomyomatosis.

    abstract:INTRODUCTION:Lymphangioleiomyomatosis (LAM) is a destructive lung disease affecting primarily women. LAM is caused by inactivating mutations in the tuberous sclerosis complex (TSC) genes, resulting in hyperactivation of mechanistic/mammalian target of rapamycin complex 1 (mTORC1). Over the past five years, there have b...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1409622

    authors: Nijmeh J,El-Chemaly S,Henske EP

    更新日期:2018-02-01 00:00:00

  • Respiratory muscle involvement in sarcoidosis.

    abstract:INTRODUCTION:In sarcoidosis, muscle involvement is common, but mostly asymptomatic. Currently, little is known about respiratory muscle and diaphragm involvement and function in patients with sarcoidosis. Reduced inspiratory muscle strength and/or a reduced diaphragm function may contribute to exertional dyspnea, fatig...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1480940

    authors: Schreiber T,Windisch W

    更新日期:2018-07-01 00:00:00

  • Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies.

    abstract::Introduction: Idiopathic pulmonary fibrosis (IPF), the most common of the idiopathic interstitial pneumonias, is a disease with a poor prognosis, and a highly heterogeneous and unpredictable clinical course. While most patients experience a relatively slow clinical, functional and radiological deterioration, a signifi...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1080/17476348.2020.1724096

    authors: Biondini D,Balestro E,Sverzellati N,Cocconcelli E,Bernardinello N,Ryerson CJ,Spagnolo P

    更新日期:2020-04-01 00:00:00

  • Therapy for cough: where does it fall short?

    abstract::Studies on cough have come a long way but many shortfalls still exist. These shortfalls can be attributed to: the lack of randomized controlled studies with a focus on cough; studies not using robust cough outcome measures, poor definition of target groups in studies and guidelines, the lack of safe and efficacious tr...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.11.35

    authors: Chang AB

    更新日期:2011-08-01 00:00:00

  • Biomarkers of latent TB infection.

    abstract::For the last 100 years, the tuberculin skin test (TST) has been the only diagnostic tool available for latent TB infection (LTBI) and no biomarker per se is available to diagnose the presence of LTBI. With the introduction of M. tuberculosis-specific IFN-gamma release assays (IGRAs), a new area of in vitro immunodiagn...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/ers.09.31

    authors: Ruhwald M,Ravn P

    更新日期:2009-08-01 00:00:00

  • Improving quality of life for patients with terminal respiratory disease.

    abstract::Chronic respiratory disease is an increasingly prevalent cause of life-limiting illness. Care for patients with terminal respiratory diseases has historically focused on disease-modifying therapies, many of which have little impact on life expectancy. This exclusive focus can detract from attention to patient-physicia...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/ers.09.47

    authors: Isaac M,Curtis JR

    更新日期:2009-12-01 00:00:00

  • Ultrasound in the management of pleural disease.

    abstract:INTRODUCTION:Pleural disease encompasses a large range of conditions, is a common presentation to the acute medical take and often requires comprehensive investigation and treatment. Ultrasound is well recognised as a useful investigative tool in pleural disease especially in the field of pleural effusion, pleural thic...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2017.1300531

    authors: Mercer RM,Psallidas I,Rahman NM

    更新日期:2017-04-01 00:00:00

  • The role of desmosines as biomarkers for chronic obstructive pulmonary disease.

    abstract::Since chronic obstructive pulmonary disease (COPD) has a progressive and major impact on health management, many aspects of this disorder, including development of effective and reliable biomarkers to monitor disease progression, are under intensive investigation. A huge amount of data, accumulated over the years, hav...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.13.4

    authors: Iadarola P,Luisetti M

    更新日期:2013-04-01 00:00:00

  • Acute oxygen therapy: a cross-sectional study of prescribing practices at an English hospital immediately before COVID-19 pandemic.

    abstract:BACKGROUND:Approximately 14% of UK hospital in-patients receive supplemental oxygen therapy, only 57% have valid prescriptions. Oxygen must be optimally prescribed to ensure maximal therapeutic response whilst minimizing adverse outcomes (including fatality). This study investigates prescription compliance. METHODS:Al...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1080/17476348.2021.1826316

    authors: Barrett R,Catangui E,Scott R

    更新日期:2020-10-14 00:00:00

  • The emerging phenomenon of electronic cigarettes.

    abstract::The need for novel and more effective approaches to tobacco control is unquestionable. The electronic cigarette is a battery-powered electronic nicotine delivery system that looks very similar to a conventional cigarette and is capable of emulating smoking, but without the combustion products accountable for smoking's...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.11.92

    authors: Caponnetto P,Campagna D,Papale G,Russo C,Polosa R

    更新日期:2012-02-01 00:00:00

  • Perspectives in adjuvant chemotherapy in NSCLC.

    abstract::In 2007 the long-term outcome of lung cancer is still disappointing, with a 5-year survival rate not exceeding 15%. However, small but significant improvements in survival times have been achieved in the last decade. This progress has been achieved through the improvement of surgical techniques and following the intro...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.1.1.99

    authors: Selvaggi G,Scagliotti GV

    更新日期:2007-08-01 00:00:00

  • Long-term oxygen therapy.

    abstract::Long-term oxygen therapy (LTOT) has been shown to reduce pulmonary hypertension and improve survival in patients with chronic obstructive pulmonary disease and resting hypoxemia (reduced arterial partial pressure of oxygen ≤55 mmHg). However, the benefit of its use for chronic pulmonary diseases other than chronic obs...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.12.69

    authors: Jindal SK,Agarwal R

    更新日期:2012-12-01 00:00:00

  • Infection in cystic fibrosis: impact of the environment and climate.

    abstract::In many countries numbers of adults with cystic fibrosis (CF) exceed that of children, with median survival predicted to surpass 50 years. Increasing longevity is, in part, due to intensive therapies including eradication of early infection and suppressive therapies and pulmonary exacerbations. Initial infections with...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/17476348.2016.1162715

    authors: Ramsay KA,Stockwell RE,Bell SC,Kidd TJ

    更新日期:2016-01-01 00:00:00

  • Which is the optimal bronchodilator therapy for chronic obstructive pulmonary disease?

    abstract::Chronic obstructive pulmonary disease is an inflammatory disorder characterized by airflow limitation. Its cardinal symptom is dyspnea, which develops gradually with even low levels of exercise. Bronchodilators (BDs) are the most effective drugs for relieving dyspnea. Two main types of BD are currently available, β-mi...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.13.18

    authors: Baloira A

    更新日期:2013-04-01 00:00:00

  • Asthma-related comorbidities.

    abstract::Asthma is often associated with various comorbidities. The most frequently reported asthma comorbid conditions include rhinitis, sinusitis, gastroesophageal reflux disease, obstructive sleep apnea, hormonal disorders and psychopathologies. These conditions may, first: share a common pathophysiological mechanism with a...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1586/ers.11.34

    authors: Boulet LP,Boulay MÈ

    更新日期:2011-06-01 00:00:00

  • Treatment in resectable, locally advanced NSCLC: which is the best approach?

    abstract::Non-small-cell lung cancer is the most common cause of cancer-related death worldwide. Surgery remains the cornerstone of treatment for localized, resectable lung cancer, although advanced stages are associated with a high risk of developing distant metastases. Large randomized trials have demonstrated an improvement ...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章

    doi:10.1586/17476348.2.5.655

    authors: Kueng MM,Betticher DC

    更新日期:2008-10-01 00:00:00

  • The challenge of avoiding intubation in immunocompromised patients with acute respiratory failure.

    abstract:INTRODUCTION:A growing number of immunocompromised (IC) patients with acute hypoxemic respiratory failure (ARF) is admitted to the intensive care unit (ICU) worldwide. Areas covered: This review provides an overview of the current knowledge of the ways to prevent intubation in IC patients with ARF. Expert commentary: S...

    journal_title:Expert review of respiratory medicine

    pub_type: 杂志文章,评审

    doi:10.1080/17476348.2018.1511430

    authors: De Jong A,Calvet L,Lemiale V,Demoule A,Mokart D,Darmon M,Jaber S,Azoulay E

    更新日期:2018-10-01 00:00:00